Clinical News
-
WARM AUTOIMMUNE HAEMOLYTIC ANAEMIA | FDA Approves First Disease-Specific Treatment
Warm autoimmune haemolytic anaemia is an acquired autoimmune disorder in which immunoglobulin G (IgG) autoantibodies mistakenly attach to red blood cells and mark them for destruction at normal body temperature.…
Read More » -
GLOBAL HEMATOLOGY | TIF Publishes EHA 2026 Key Takeaways
As a vital annual milestone, EHA2026 united thousands of hematologists, clinical researchers, and advocates from across the globe to address critical breakthroughs in the research, management, and cure of hematological…
Read More » -
RARE ANAEMIAS | RAIN Publishes EHA 2026 Research Highlights
Compiled by TIF’s Medical Advisor Dr. Michael Angastiniotis, and TIF’s Deputy Director, Ms. Lily Cannon, the publication offers a clear, patient-focused overview of recent developments across a broad spectrum of…
Read More » -
EU APPROVES MITAPIVAT | A New Treatment Milestone for Adults with α- or β-Thalassaemia
This decision is of particular importance because it covers a broad adult thalassaemia population, including both alpha- and beta-thalassaemia and both transfusion-dependent and non-transfusion-dependent disease. According to Agios Pharmaceuticals’ official…
Read More » -
APLASTIC ANAEMIA | ASH Publishes Guidelines on Diagnosis and Management of Severe and Very Severe Disease
Aplastic anaemia is a rare disorder characterized by bone marrow failure and reduced production of blood cells, resulting in pancytopenia and increased risks of infection, bleeding, and fatigue. Severe and…
Read More » -
wAIHA | Rilzabrutinib Receives FDA Breakthrough Therapy Designation
Warm autoimmune haemolytic anaemia is a rare autoimmune disorder characterized by the premature destruction of red blood cells, leading to anemia and other serious complications, such as significant fatigue, dizziness,…
Read More » -
wAIHA | Sovleplenib Demonstrates Positive Phase III Clinical Results
wAIHA is a rare autoimmune disorder in which the immune system produces antibodies that mistakenly target and destroy red blood cells, leading to anemia and significant clinical burden. The…
Read More » -
SICKLE CELL DISEASE | Alzheimer’s Drug Demonstrates Potential Therapeutic Benefit
The study explores the potential of memantine, a medication that has been safely used for many years in the treatment of Alzheimer’s disease. Researchers investigated whether this well-known, affordable drug…
Read More » -
FDA APPROVES AQVESME™ (mitapivat) | First Oral Therapy for Anaemia Across All Forms of Thalassaemia
This regulatory decision marks a landmark milestone in the management of thalassaemia, as AQVESME is now the first and only therapy approved in the United States indicated for treating anaemia…
Read More » -
PUTTING PATIENTS FIRST IN CLINICAL RESEARCH | New EU Recommendations to Reduce Trials Bureaucracy
As Prof. Martin Dreyling, Chair of the Coalition for Reducing Bureaucracy, explains: “The current safety requirements for investigators are disproportionately burdensome, to the point that they may obscure relevant safety…
Read More »